Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion

被引:27
作者
Agostini, Carlo [1 ]
Blau, Igor-Wolfgang [2 ]
Kimby, Eva [3 ]
Plesner, Torben [4 ,5 ]
机构
[1] Univ Padua, Dept Med DIMED, Clin Immunol, Padua, Italy
[2] Charite Univ Med Berlin, Dept Med, Div Hematol Oncol & Tumor Immunol, Berlin, Germany
[3] Karolinska Inst, Dept Med, Stockholm, Sweden
[4] Univ Southern Denmark, Inst Reg Hlth Sci, Vejle, Denmark
[5] Univ Southern Denmark, Vejle Hosp, Dept Hematol, Sect Internal Med, Vejle, Denmark
关键词
Secondary immune deficiencies; immunoglobulin replacement; IVIG; SCIG; fSCIG; expert opinion; recommendations; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL DEPLETION; INTRAVENOUS IMMUNOGLOBULIN; MULTIPLE-MYELOMA; RITUXIMAB TREATMENT; INFLUENZA VACCINE; HYPOGAMMAGLOBULINEMIA; INFECTION; GLOBULIN; SURVIVAL;
D O I
10.1080/1744666X.2016.1208085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: In primary immunodeficiency (PID), immunoglobulin replacement therapy (IgRT) for infection prevention is well-established and supported by a wealth of clinical data. On the contrary, very little evidence-based data is available on the challenges surrounding the use of IgRT in secondary immune deficiencies (SID), and most published guidelines are mere extrapolations from the experience in PID.Areas covered: In this article, four European experts provide their consolidated opinion on open questions surrounding the prophylactic use of IgRT in SID, based on their clinical experience. The main topics are IgRT initiation, route of administration, dose optimization, and therapy discontinuation. The authors hope this discussion will be of assistance to practicing physicians in their daily decision-making.Expert commentary: Although growing experience indicates that IgRT could play an important role in the management of SID, very little robust evidence is available to guide clinical practice. The authors stress the urgent need for new studies in the field and discuss points they find of importance to design them adequately.
引用
收藏
页码:921 / 926
页数:6
相关论文
共 60 条
[1]   Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience [J].
Abrisqueta, Pau ;
Pereira, Arturo ;
Rozman, Ciril ;
Aymerich, Marta ;
Gine, Eva ;
Moreno, Carol ;
Muntanola, Ana ;
Rozman, Maria ;
Villamor, Neus ;
Hodgson, Kate ;
Campo, Elias ;
Bosch, Francesc ;
Montserrat, Emili .
BLOOD, 2009, 114 (10) :2044-2050
[2]   Assessment and clinical interpretation of reduced IgG values [J].
Agarwal, Shradha ;
Cunningham-Rundles, Charlotte .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 99 (03) :281-283
[3]   Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy [J].
Ammann, Eric M. ;
Jones, Michael P. ;
Link, Brian K. ;
Carnahan, Ryan M. ;
Winiecki, Scott K. ;
Torner, James C. ;
McDowell, Bradley D. ;
Fireman, Bruce H. ;
Chrischilles, Elizabeth A. .
BLOOD, 2016, 127 (02) :200-207
[4]   Guidelines on the use of intravenous immune globulin for hematologic conditions [J].
Anderson, David ;
Ali, Kaiser ;
Blanchette, Victor ;
Brouwers, Melissa ;
Couban, Stephen ;
Radmoor, Paula ;
Huebsch, Lothar ;
Hume, Heather ;
McLeod, Anne ;
Meyer, Ralph ;
Moltzan, Catherine ;
Nahirniak, Susan ;
Nantel, Stephen ;
Pineo, Graham ;
Rock, Gail .
TRANSFUSION MEDICINE REVIEWS, 2007, 21 (02) :S9-S56
[5]   Risk factors for hypogammaglobulinemia after allo-SCT [J].
Arai, Y. ;
Yamashita, K. ;
Mizugishi, K. ;
Kondo, T. ;
Kitano, T. ;
Hishizawa, M. ;
Kadowaki, N. ;
Takaori-Kondo, A. .
BONE MARROW TRANSPLANTATION, 2014, 49 (06) :859-861
[6]  
Australia NBA, 2012, CRIT CLIN US INTR IM
[7]   Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies [J].
Bayry, Jagadeesh ;
Fournier, Emilie M. ;
Maddur, Mohan S. ;
Vani, Janakiraman ;
Wootla, Bharath ;
Siberil, Sophie ;
Dimitrov, Jordan D. ;
Lacroix-Desmazes, Sebastien ;
Berdah, Mikael ;
Crabol, Yoann ;
Oksenhendler, Eric ;
Levy, Yves ;
Mouthon, Luc ;
Sautes-Fridman, Catherine ;
Hermine, Olivier ;
Kaveri, Srini V. .
JOURNAL OF AUTOIMMUNITY, 2011, 36 (01) :9-15
[8]   Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens [J].
Bedognetti, Davide ;
Zoppoli, Gabriele ;
Massucco, Carlotta ;
Zanardi, Elisa ;
Zupo, Simonetta ;
Bruzzone, Andrea ;
Sertoli, Mario Roberto ;
Balleari, Enrico ;
Racchi, Omar ;
Messina, Marco ;
Caltabiano, Graziano ;
Icardi, Giancarlo ;
Durando, Paolo ;
Marincola, Francesco M. ;
Boccardo, Francesco ;
Ferrarini, Manlio ;
Ansaldi, Filippo ;
De Maria, Andrea .
JOURNAL OF IMMUNOLOGY, 2011, 186 (10) :6044-6055
[9]   Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia [J].
Björkander, J ;
Nikoskelainen, J ;
Leibl, H ;
Lanbeck, P ;
Wallvik, J ;
Lumio, JT ;
Braconier, JH ;
Pavlova, BG ;
Birthistle, K ;
Engl, W ;
Walter, S ;
Ehrlich, HJ .
VOX SANGUINIS, 2006, 90 (04) :286-293
[10]   Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections [J].
Casulo, Carla ;
Maragulia, Jocelyn ;
Zelenetz, Andrew D. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (02) :106-111